Viatris
VTRS
$15.95
+2.77%
Viatris Inc. is a global pharmaceutical company formed from the merger of Pfizer's Upjohn division and Mylan, operating in the specialty and generic drug manufacturing industry. It is a major player in the global generics and biosimilars market, with a significant portfolio of legacy brand-name drugs like Lipitor and Viagra, positioning it as a large-scale, diversified provider of both off-patent and complex medicines. The current investor narrative centers on the company's ongoing transformation, including portfolio optimization and debt reduction, amidst volatile quarterly earnings and a challenging pricing environment for generics, as evidenced by recent financial results showing significant net losses despite revenue growth.…
VTRS
Viatris
$15.95
VTRS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viatris's 12-month outlook, with a consensus price target around $20.73 and implied upside of +30.0% versus the current price.
Average Target
$20.73
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$13 - $21
Analyst target range
Analyst coverage for Viatris is limited, with only two analysts providing estimates for future revenue, indicating this is a stock with subdued institutional research interest, which can lead to higher volatility and less efficient price discovery. The available data shows a consensus revenue estimate for the next period of approximately $14.97 billion, with a low estimate of $14.78 billion and a high of $15.11 billion, representing a relatively tight range that suggests some agreement on the top-line outlook. Recent institutional rating actions show a mixed but generally stable picture, with Barclays maintaining an 'Overweight' in March 2026 and Argus Research upgrading to 'Buy' from 'Hold' in January 2026, counterbalanced by firms like BofA Securities maintaining an 'Underperform' rating, reflecting the ongoing debate between the stock's deep value and its operational challenges.
Bulls vs Bears: VTRS Investment Factors
The investment debate for Viatris is a classic clash between deep value and broken fundamentals. The bull case, currently supported by stronger technical and sentiment momentum, rests on an extreme valuation discount (PS of 1.02) and robust cash flow, suggesting the market is overly pessimistic. The bear case is grounded in the severe and persistent profitability crisis, with negative margins and volatile revenue. The single most important tension is whether management's portfolio optimization and cost initiatives can successfully arrest the margin erosion and deliver consistent profitability. If they can, the valuation multiple has significant room to expand. If they cannot, the current price near 52-week highs may prove unsustainable despite the low sales multiple.
Bullish
- Extreme Valuation Discount: VTRS trades at a trailing Price-to-Sales ratio of 1.02, a dramatic compression from its historical PS of 3.87 and well below typical pharmaceutical company multiples. This deep discount suggests the market has priced in a worst-case scenario, offering significant upside potential if fundamentals merely stabilize.
- Robust Free Cash Flow Generation: Despite net losses, the company generated $1.82 billion in trailing twelve-month free cash flow. This strong cash generation provides ample liquidity to support its 3.85% dividend yield, fund strategic portfolio optimization, and reduce its moderate debt-to-equity ratio of 1.00.
- Strong Technical Momentum: The stock is in a powerful uptrend, up 77.57% over the past year and trading at 91% of its 52-week high of $16.47. Its beta of 0.822 indicates this appreciation has been achieved with 18% less volatility than the broader market, suggesting a relatively stable ascent.
- Positive Analyst Upgrades: Recent institutional sentiment has improved, with Argus Research upgrading VTRS to 'Buy' from 'Hold' in January 2026 and Barclays maintaining an 'Overweight' rating in March 2026. This indicates a growing belief in the company's transformation narrative and deep-value proposition.
Bearish
- Severe and Persistent Profitability Crisis: VTRS reported a Q4 2025 net loss of $340.1M, with a trailing net margin of -24.58% and a deeply negative ROE of -23.89%. Gross margin compressed sharply from 36.83% in Q3 to 30.63% in Q4, indicating intense pricing pressure and an inability to translate revenue into earnings.
- Volatile and Modest Revenue Growth: While Q4 revenue grew 4.97% YoY to $3.70B, this follows a volatile pattern, including a sequential decline from Q3's $3.76B. This inconsistency, coupled with a challenging generics pricing environment, calls into question the sustainability of top-line expansion.
- Limited Analyst Coverage & Visibility: Only two analysts provide revenue estimates for VTRS, indicating subdued institutional research interest. This can lead to higher volatility, less efficient price discovery, and a lack of consensus confidence in the company's forward path.
- High Short Interest: A short ratio of 3.99 reflects significant skepticism in the market about the sustainability of the recent rally. This creates a technical overhang and potential for sharp downside moves if the bullish narrative falters.
VTRS Technical Analysis
Viatris is in a strong, sustained uptrend, with the stock price surging 77.57% over the past year. As of the latest close at $15.04, the stock is trading at approximately 91% of its 52-week high of $16.47, indicating it is near the top of its annual range and reflecting significant bullish momentum, though it also suggests potential for overextension. The recent momentum is positive but shows signs of consolidation; the stock gained 10.34% over the past month and 14.90% over the past three months, which, while strong, is a deceleration from the explosive 45.17% six-month gain, hinting at a potential pause or digestion of prior gains. Key technical support is anchored at the 52-week low of $8.19, while immediate resistance sits at the 52-week high of $16.47; a decisive breakout above $16.47 would signal a continuation of the powerful uptrend, while a failure could lead to a test of lower support levels. With a beta of 0.822, Viatris exhibits approximately 18% less volatility than the broader market, which is notable given its significant price appreciation and suggests its moves, while large, are somewhat dampened relative to the S&P 500.
Beta
0.87
0.87x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$8-$16
Price range past year
Annual Return
+88.1%
Cumulative gain past year
| Period | VTRS Return | S&P 500 |
|---|---|---|
| 1m | +18.9% | +11.4% |
| 3m | +11.2% | +8.3% |
| 6m | +57.6% | +9.4% |
| 1y | +88.1% | +31.3% |
| ytd | +28.0% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTRS Fundamental Analysis
Revenue growth is present but modest and inconsistent; the most recent Q4 2025 revenue was $3.70 billion, representing a 4.97% year-over-year increase, yet this follows a volatile pattern where the prior quarter (Q3 2025) saw revenue of $3.76 billion. Segment data shows the 'Brands' portfolio generated $2.35 billion versus $1.34 billion for 'Generics', indicating the legacy brand business is the primary revenue driver, though growth is likely pressured by generic competition. The company is currently unprofitable on a net income basis, with a Q4 2025 net loss of $340.1 million and a trailing twelve-month net margin of -24.58%. Gross margin for the quarter was 30.63%, which has compressed from 36.83% in Q3 2025, indicating significant pressure on profitability, likely from pricing and mix challenges in its generics business. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.00, indicating a balanced capital structure. Financial health is supported by robust cash generation, with trailing twelve-month free cash flow of $1.82 billion, providing ample liquidity for dividends, debt repayment, and share buybacks, as evidenced by the current ratio of 1.30 and an ROA of 1.96%, which, while positive, is offset by a deeply negative ROE of -23.89% due to the net losses.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTRS Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Viatris trades at a trailing PS ratio of 1.02, which is substantially below the historical PS ratio of 3.87 from the end of Q4 2025, indicating a dramatic compression in the sales multiple over recent months. Compared to common sector benchmarks, a PS ratio around 1.0 is generally considered low for a pharmaceutical company, suggesting the market is assigning a significant discount, likely due to the profitability challenges and the low-growth nature of its off-patent portfolio. Historically, the stock's own valuation has collapsed from recent highs; the current PS of 1.02 is near the very bottom of its observable historical range (data shows ratios above 3.0 were common in 2024-2025), signaling the market may be pricing in a pessimistic scenario of permanent margin erosion or stagnant growth, presenting a potential deep-value opportunity if fundamentals stabilize.
PE
-4.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -569x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-70.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the company's severe and persistent lack of profitability, with a trailing net margin of -24.58% and a Q4 gross margin that compressed 620 basis points sequentially to 30.63%. This indicates fundamental pricing and cost structure challenges, particularly in its generics segment. While free cash flow is strong at $1.82B TTM, this is being generated despite net losses, a situation that may not be sustainable long-term without a turnaround in earnings. Revenue concentration in low-growth, off-patent legacy brands (60% of sales) further limits organic growth potential and exposes the company to ongoing competitive and pricing pressures.
Market & Competitive Risks: The stock's 77.57% one-year surge places it near its 52-week high, creating valuation compression risk if earnings fail to materialize to justify the rally. Trading at a PS of 1.02, the stock is cheap historically, but the sector benchmark is unclear; if peers trade at higher multiples due to profitability, VTRS may remain discounted. The generics industry faces perpetual pricing pressure and competition, threatening the 40% of revenue from that segment. The stock's beta of 0.822 suggests it is less volatile than the market, but its high short ratio of 3.99 indicates a skeptical investor base that could accelerate selling on negative news.
Worst-Case Scenario: The worst-case scenario involves a failure of the strategic transformation, leading to continued gross margin compression, another significant quarterly net loss that erodes cash reserves, and a downgrade of growth expectations by the few covering analysts. This could trigger a rapid unwind of the year-long rally as momentum investors exit and short sellers press their bets. A realistic downside could see the stock re-test its 52-week low of $8.19, representing a potential loss of approximately -46% from the current price of $15.04. The recent maximum drawdown of -19.65% shows the stock is capable of sharp corrections even within an uptrend.